English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 1 February 2022, 17:43 JST
Share:
    

Source: Eisai
Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021

TOKYO, Feb 1, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it was selected as the winner of the Tokyo Governor Prize for Corporate Governance of the Year 2021, which is an award program organized by the Japan Association of Corporate Directors (JACD). The award ceremony was held on January 31, 2022.

Left: Mr. Eiichiro Kodama: Director General for Global Financial City Strategy, Office of the Governor for Policy Planning, Tokyo Metropolitan Government, Right: Haruo Naito: CEO, "Eisai"

The awards have been established to recognize the companies which have achieved and maintained the medium to long term profitability by implementing good corporate governance, since 2015. Among the eligible companies for selection of the Corporate Governance of the Year 2021, the Tokyo Governor Prize goes to a company which has excellent corporate governance and also practices ESG activities such as environmental activities, women empowerment, initiatives for diversity and work style reforms.

Commenting on the reason for selecting Eisai, Mr. Eiichiro Kodama, Director General for Global Financial City Strategy, Office of the Governor for Policy Planning, Tokyo Metropolitan Government stated, "Eisai is a pioneer in incorporating its corporate philosophy into the Articles of Incorporation and practicing "Purpose Management." With regard to corporate governance, Eisai makes the most of its status as a company with a nomination committee, etc., system to clearly separate management oversight and business execution, and places great importance to dialogue with its stakeholders including patients. In terms of ESG, Eisai is a signatory to the United Nations Global Compact and actively participates in climate change-related initiatives such as "RE100" and the Japan Climate Initiative. In addition, Eisai is taking on the challenge of quantifying values that do not appear on the balance sheet, such as investments in human capital, with attempting to select KPIs related ESG including the ratio of women in management positions, analyze its relationship with PBR (Price Book-value Ratio), and utilize the verification results for engagement with investors. Eisai is actively working to tell the story of the cause-and-effect relationship between the ESG initiatives and the enhancement of corporate value, thus taking on the extremely important challenge to visualize invisible value, embody the value of ESG, and disseminate them."

Eisai defines its corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides" in the Articles of Incorporation, and shares it with its stakeholders. Eisai calls this philosophy the human health care (hhc) philosophy, in one word, and believes that practicing philosophical management based on the hhc philosophy will contribute to achieving Sustainable Development Goals (SDGs) and further enhance its corporate value.

Eisai is committed to further strengthening its corporate governance in order to realize the hhc philosophy.

For further information on the awards, please visit www.jacd.jp/en/conference.

*Corporate Governance of the Year is a registered trademark of JACD

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Releated News
Tuesday, 4 October 2022, 16:44 JST
Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
2022年10月4日 15時00分 JST
エーザイ、川島工園において新注射剤棟/研究棟が竣工
Wednesday, 28 September 2022, 15:15 JST
Eisai's Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint
2022年9月28日 9時00分 JST
エーザイ、レカネマブがグローバル大規模臨床第III相CLARITY AD検証試験で統計学的に高度に有意な臨床症状の悪化抑制を示し、主要評価項目を達成
Monday, 26 September 2022, 20:14 JST
Eisai: Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575